Security key
98420X202
X4 Pharmaceuticals, Inc - COMMON STOCK (XFOR)
CUSIP: 98420X202
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 2,150,633
- Total 13F value
- $4,086,190
- Share change
- +2,066,952
- SEC-reported price per share
- $1.90
- Number of holders
- 49
- Value change
- +$4,064,925
- Number of buys
- 47
- Number of sells
- 2
- Shares outstanding
- 99,100,348
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
49
Top holders
10
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2026
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X202
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 Pharmaceuticals, Inc - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
Bain Capital Life Science...
Comparable rows
2/15
Latest evidence
31 Mar 2025
13F
13D/G
3/4/5
Lead comparable stake: 4.8%
13 rows are not safely comparable across share classes.
13D/G row: VANGUARD GROUP INC
Showing 1-6 of 15 holder rows.
Quick read
VANGUARD GROUP INC leads the comparable SEC ownership view at 4.8%.
2 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Comparable ownership
Top 2
VANGUARD GROUP INC
4.8%
ORBIMED ADVISORS LLC
1.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
13D/G
Company · The Vanguard Group
|
4.8%
Reported 13D/G
· 31 Dec 2024
|
$1,903,935
8,067,516 shares
|
— | 31 Mar 2025 |
| ORBIMED ADVISORS LLC |
13F
13D/G
Company
|
1.7%
Reported 13D/G
· 30 Jun 2025
|
$1,601,968
6,776,515 shares
|
— | 31 Mar 2025 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
—
denominator unverified
|
$3,998,891
16,915,784 shares
|
— | 31 Mar 2025 |
| NEA Management Company, LLC |
13F
Company
|
—
denominator unverified
|
$3,542,878
14,986,793 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
Company
|
—
denominator unverified
|
$2,702,123
11,430,304 shares
|
— | 31 Mar 2025 |
| ACORN CAPITAL ADVISORS, LLC |
13F
Company
|
—
denominator unverified
|
$1,754,556
7,310,650 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
49
Shares
2,150,633
Rows available
49
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
2
Q2 2025 holders
49
Holder diff
47
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend